Cargando…

Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease

Detalles Bibliográficos
Autores principales:	Patoulias, Dimitrios, Imprialos, Konstantinos, Stavropoulos, Konstantinos, Doumas, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759434/ https://www.ncbi.nlm.nih.gov/pubmed/31142103 http://dx.doi.org/10.3350/cmh.2019.0034

Ejemplares similares

COVID-19: The Waterloo of governments, healthcare systems, and large health organizations
por: Doumas, Michael, et al.
Publicado: (2020)

Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?
por: Reklou, Andromachi, et al.
Publicado: (2018)

COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?
por: Doumas, Michael, et al.
Publicado: (2020)

Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic()
por: Patoulias, D., et al.
Publicado: (2022)

The Associations between Kidney Function and Sexual Dysfunction among Males and Females with Type 2 Diabetes Mellitus
por: Katsimardou, Alexandra, et al.
Publicado: (2023)

Metaanálisis para evaluar el riesgo de infecciones respiratorias y síndrome de distrés respiratorio del adulto con los agonistas del receptor del péptido similar al glucagón tipo 1 en los ensayos de seguridad cardiovascular: consecuencias útiles para la pandemia de COVID-19
por: Patoulias, D., et al.
Publicado: (2022)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease in patients with inflammatory bowel disease might boost cardiovascular disease burden
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data
por: Athyros, Vasilios G., et al.
Publicado: (2020)

The Impact of Metabolic Syndrome Components on Erectile Function in Patients with Type 2 Diabetes
por: Katsimardou, Alexandra, et al.
Publicado: (2023)

Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2018)

Serum Resistin as a Biomarker in Nonalcoholic Fatty Liver Disease: Is This a Road to be Taken?
por: Patoulias, Dimitrios
Publicado: (2021)

Lean non-alcoholic fatty liver disease: do not forget diabetes
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2019)

Cardiovascular disease in patients with non-alcoholic fatty liver disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Liraglutide for non-alcoholic fatty liver disease in children and adolescents: has a new era arrived?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension
por: Papademetriou, Vasilios, et al.
Publicado: (2019)

Role of Leptin in Non-Alcoholic Fatty Liver Disease
por: Jiménez-Cortegana, Carlos, et al.
Publicado: (2021)

Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Recent advances in understanding and managing resistant/refractory hypertension
por: Doumas, Michael, et al.
Publicado: (2020)

Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?
por: Chandrasekharan, Karthik, et al.
Publicado: (2020)

Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Microsomal Prostaglandin E Synthase-1 and -2: Emerging Targets in Non-Alcoholic Fatty Liver Disease
por: Kotsos, Dimitrios, et al.
Publicado: (2023)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications
por: Tana, Claudio, et al.
Publicado: (2019)

Ambiguous Pathogenic Roles of Macrophages in Alcohol-Associated Liver Diseases
por: Ait Ahmed, Yeni, et al.
Publicado: (2023)

Endothelial dysfunction and COVID-19: What's the true impact on surrogate outcomes?
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Meta-Analysis Addressing the Efficacy and Safety of Antiplatelet Agents in Patients With COVID-19
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Alcohol consumption in patients with nonalcoholic fatty liver disease: yes, or no?
por: Protopapas, Adonis A., et al.
Publicado: (2021)

The association of leptin with severity of non-alcoholic fatty liver disease: A population-based study
por: Rotundo, Laura, et al.
Publicado: (2018)

Lower Circulating Leptin Levels Are Related to Non-Alcoholic Fatty Liver Disease in Children With Obesity
por: Brandt, Stephanie, et al.
Publicado: (2022)

Canakinumab: can it untie the Gordian knot of cardiovascular disease in patients with familial Mediterranean fever?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Evaluation of Serum Omentin-1, Vaspin, Leptin, Adiponectin Levels in Obese/Overweight Children and Their Relationship With Non-Alcoholic Fatty Liver Disease
por: Özkan, Esra Akyüz, et al.
Publicado: (2022)

Serum Leptin and Adiponectin: Indicators of Cardiovascular Disease Secondary to Psoriasis
por: Yan, Haoxiang, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease and cardiovascular risk
por: Patil, Rashmee, et al.
Publicado: (2017)

Association of Serum Adiponectin, Leptin, and Resistin Concentrations with the Severity of Liver Dysfunction and the Disease Complications in Alcoholic Liver Disease
por: Kasztelan-Szczerbinska, Beata, et al.
Publicado: (2013)

Sexual dysfunction among women with systemic lupus erythematosus: might it reflect cardiovascular disease burden?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jerfm8u1lumsp41ue5sv2bkoit